Cargando…

Developing core outcome sets for clinical trials: issues to consider

The selection of appropriate outcomes or domains is crucial when designing clinical trials in order to compare directly the effects of different interventions in ways that minimize bias. If the findings are to influence policy and practice then the chosen outcomes need to be relevant and important t...

Descripción completa

Detalles Bibliográficos
Autores principales: Williamson, Paula R, Altman, Douglas G, Blazeby, Jane M, Clarke, Mike, Devane, Declan, Gargon, Elizabeth, Tugwell, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3472231/
https://www.ncbi.nlm.nih.gov/pubmed/22867278
http://dx.doi.org/10.1186/1745-6215-13-132
_version_ 1782246556039118848
author Williamson, Paula R
Altman, Douglas G
Blazeby, Jane M
Clarke, Mike
Devane, Declan
Gargon, Elizabeth
Tugwell, Peter
author_facet Williamson, Paula R
Altman, Douglas G
Blazeby, Jane M
Clarke, Mike
Devane, Declan
Gargon, Elizabeth
Tugwell, Peter
author_sort Williamson, Paula R
collection PubMed
description The selection of appropriate outcomes or domains is crucial when designing clinical trials in order to compare directly the effects of different interventions in ways that minimize bias. If the findings are to influence policy and practice then the chosen outcomes need to be relevant and important to key stakeholders including patients and the public, health care professionals and others making decisions about health care. There is a growing recognition that insufficient attention has been paid to the outcomes measured in clinical trials. These issues could be addressed through the development and use of an agreed standardized collection of outcomes, known as a core outcome set, which should be measured and reported, as a minimum, in all trials for a specific clinical area. Accumulating work in this area has identified the need for general guidance on the development of core outcome sets. Key issues to consider in the development of a core outcome set include its scope, the stakeholder groups to involve, choice of consensus method and the achievement of a consensus.
format Online
Article
Text
id pubmed-3472231
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-34722312012-10-17 Developing core outcome sets for clinical trials: issues to consider Williamson, Paula R Altman, Douglas G Blazeby, Jane M Clarke, Mike Devane, Declan Gargon, Elizabeth Tugwell, Peter Trials Commentary The selection of appropriate outcomes or domains is crucial when designing clinical trials in order to compare directly the effects of different interventions in ways that minimize bias. If the findings are to influence policy and practice then the chosen outcomes need to be relevant and important to key stakeholders including patients and the public, health care professionals and others making decisions about health care. There is a growing recognition that insufficient attention has been paid to the outcomes measured in clinical trials. These issues could be addressed through the development and use of an agreed standardized collection of outcomes, known as a core outcome set, which should be measured and reported, as a minimum, in all trials for a specific clinical area. Accumulating work in this area has identified the need for general guidance on the development of core outcome sets. Key issues to consider in the development of a core outcome set include its scope, the stakeholder groups to involve, choice of consensus method and the achievement of a consensus. BioMed Central 2012-08-06 /pmc/articles/PMC3472231/ /pubmed/22867278 http://dx.doi.org/10.1186/1745-6215-13-132 Text en Copyright ©2012 Williamson et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Commentary
Williamson, Paula R
Altman, Douglas G
Blazeby, Jane M
Clarke, Mike
Devane, Declan
Gargon, Elizabeth
Tugwell, Peter
Developing core outcome sets for clinical trials: issues to consider
title Developing core outcome sets for clinical trials: issues to consider
title_full Developing core outcome sets for clinical trials: issues to consider
title_fullStr Developing core outcome sets for clinical trials: issues to consider
title_full_unstemmed Developing core outcome sets for clinical trials: issues to consider
title_short Developing core outcome sets for clinical trials: issues to consider
title_sort developing core outcome sets for clinical trials: issues to consider
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3472231/
https://www.ncbi.nlm.nih.gov/pubmed/22867278
http://dx.doi.org/10.1186/1745-6215-13-132
work_keys_str_mv AT williamsonpaular developingcoreoutcomesetsforclinicaltrialsissuestoconsider
AT altmandouglasg developingcoreoutcomesetsforclinicaltrialsissuestoconsider
AT blazebyjanem developingcoreoutcomesetsforclinicaltrialsissuestoconsider
AT clarkemike developingcoreoutcomesetsforclinicaltrialsissuestoconsider
AT devanedeclan developingcoreoutcomesetsforclinicaltrialsissuestoconsider
AT gargonelizabeth developingcoreoutcomesetsforclinicaltrialsissuestoconsider
AT tugwellpeter developingcoreoutcomesetsforclinicaltrialsissuestoconsider